Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies

Meeting the Unmet Needs in Anticoagulant Therapy

(2010)   EUROPEAN JOURNAL OF HAEMATOLOGY

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone

(2010) H Avet-Loiseau et al.   LEUKEMIA

Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients

(2009) M. Varettoni et al.   ANNALS OF ONCOLOGY

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13

(2009) D. Reece et al.   BLOOD

Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)

(2009) S. Knop et al.   BLOOD

Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone

(2009) P. Kapoor et al.   BLOOD

De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience

(2009) C. S. Tam et al.   BLOOD

Gastrosplenic Fistula From Hodgkin's Lymphoma

(2009) Carolyn D. Seib et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma

(2009) Paul G. Richardson et al.   JOURNAL OF CLINICAL ONCOLOGY

The impact of extramedullary disease at presentation on the outcome of myeloma

(2009) Ping Wu et al.   LEUKEMIA & LYMPHOMA

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

(2008) M. Wang et al.   BLOOD

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

(2008) Pieter Sonneveld et al.   CANCER